Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients

• Sponsor: VGX Pharmaceuticals, LLC (Industry)
• Overall Status: Completed
• CT.gov ID: NCT00255177
• Collaborator: (none)
• Enrollment: 44
• Locations: 4
• Arms: 4
• Duration (Months): 26
• Patients Per Site: 11
• Patients Per Site Per Month: 0.4

Study Details

Study Description

Brief Summary

Hepatitis C virus (HCV) infects approximately 170 million people worldwide. The current standard- of- care therapy of chronic HCV infection is a regimen of subcutaneously administered (pegylated)-interferon-α and ribavirin for 24 weeks (for genotypes 2 and 3) to 48 weeks (for genotype 1). The sustained viral response rates (SVR) in patients infected with genotypes 2 and 3 are ~80% but remain <50% in patients infected with genotype 1. The treatment is quite toxic with approximately 30% of patients experiencing adverse events (i.e. depression, fever, anemia, fatigue) requiring dose reduction or discontinuation of therapy. This regimen is contraindicated in women who are pregnant and in patients with decompensated liver disease. The absence of acceptable therapies for many patients with HCV infections makes new therapies desirable for this disease.

Condition or Disease	Intervention/Treatment	Phase
Hepatitis C Virus Infection	Drug: VGX-410 (Mifepristone); Drug: Placebo	Phase 2

Detailed Description

The 341-nucleotide 5' non-translated region is the most conserved part of the hepatitis C virus (HCV) genome. It contains a highly structured internal ribosomal entry site (IRES) that mediates cap-independent initiation of translation of the viral polyprotein by a mechanism that is unprecedented in eukaryotes. The first step in translation initiation is assembly of eukaryotic initiation factor (eIF) 3, eIF2, GTP, initiator tRNA and a 40S ribosomal subunit into a 43S preinitiation complex (1, 2). The IRES contains sites that bind independently with the eIF3 and 40S ribosomal subunit components of 43S complexes, and structural determinants that ensure the correct spatial orientation of these binding sites so that the 48S complex assembles precisely at the initiation codon. Since inhibiting this early translation of viral protein should block HCV replication downstream, this early critical step in replication is of great interest as a drug target. All genotypes of HCV use the same pathway; this drug target should be effective for all HCV genotypes.

VGX-410 represents the first drug in a novel class of HCV IRES inhibitors under development. VGX-410 is an orally active and bioavailable, small-molecule, organic drug. Because a related formulation of mifepristone has been previously approved by the FDA for another indication (medical abortion), there are pre-existing data from animal toxicity tests showing the safety of this compound at very high doses (5 mg/kg for 6 months in rats and macaques). In addition, chronic administration (up to 200 mg/day) of this compound for the experimental treatment of a variety of malignant and non-malignant conditions has been well tolerated in non-HCV-infected subjects for up to 1 year (3-6).

In cell culture tests, VGX-410 has been shown to be effective in inhibiting HCV replication with the 50% and 90% effective antiviral concentrations (EC50 and EC90) of 2 and 10 μM, respectively. Furthermore, VGX-410 was shown to act synergistically with interferon-a (IFN-a), the most widely-used drug treatment option available today. When used in combination with a low dose IFN-a at 1 IU/ml, EC90 of VGX-410 was reduced to 3 µM. Moreover, since VGX-410 inhibits viral replication by blocking the cellular protein complex for HCV IRES, there is reduced potential for viral mutation and resistance to this drug.

From these in vitro data, we would expect to observe 50 to 90% anti-HCV effects in humans at serum drug concentrations of 2 to 10 μM, respectively. Moreover, we compiled the drug concentration results from several previously-reported clinical data on the level of steady-state concentrations in patients who took repeat daily doses of mifepristone (>4 days). For instance, repeated oral administration of 100 and 200-mg mifepristone daily for 4 days achieved maximum plasma levels of 4.5 and 5.4 μM, respectively (9).

Study Design

• Study Type: Interventional
• Actual Enrollment: 44 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients
• Study Start Date: Nov 1, 2005
• Actual Primary Completion Date: Sep 1, 2007
• Actual Study Completion Date: Jan 1, 2008

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Placebo	Drug: Placebo; Placebo for VGX-410 tablets taken daily or twice daily for 28 days
Active Comparator: 150 mg daily	Drug: VGX-410 (Mifepristone); VGX-410 tablets taken daily or twice daily for 28 days; Other Names: Mifepristone
Active Comparator: 300mg daily	Drug: VGX-410 (Mifepristone); VGX-410 tablets taken daily or twice daily for 28 days; Other Names: Mifepristone
Active Comparator: 300mg twice daily	Drug: VGX-410 (Mifepristone); VGX-410 tablets taken daily or twice daily for 28 days; Other Names: Mifepristone

Outcome Measures

Primary Outcome Measures

1. Mean Log Change in Viral Load From Baseline (Day 1) to Day 28 [Baseline (Day 1) to Day 28]

   Mean log change in HCV RNA viral load (significant reduction is considered >0.5 log 10) from baseline (Day 1) following once or twice daily dosing for 28 days at the 28 day timepoint

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Hepatitis C infection for ≥ 1 year. Viral load at entry will be measured by the Amplicor Hepatitis C Virus Test Version 2.0 (Roche Molecular Systems; Plesasanton, CA) and genotyped by Trugene HCV 5'NC Genotyping kit (Visible Genetics; Toronto, Canada) performed within 90 days prior to study entry by a lab(s) certified for the assays.

• Male or female ages 18-65 years, inclusive.

• Plasma hepatitis C RNA of >105 copies/mL (or equivalent international units)

• Laboratory values: stable hepatic, renal, and hematological indices obtained within 30 days prior to study entry, as follows:

• Absolute neutrophil count (ANC) >= 750/mm³

• Hemoglobin >= 10.0 g/dL

• Platelet count >= 100,000/mm3

• Creatinine <= 2 x ULN

• AST (SGOT), ALT (SGPT), and alkaline phosphatase <= 3 x ULN

• Total bilirubin <= 3 x ULN

• Albumin >= 3 g/dL

• Normal PT and PTT

• Serum lipase <= 1.5 x ULN

• TSH within normal limits (0.5-6.0 mIU/L)

• Morning plasma cortisol >= 20 µg/dL

• Normal fasting glucose

• Urinalysis free of clinically significant abnormalities NOTE: Fasting is defined as no oral intake except water for at least 8 hours prior to the study visit.

• Female subjects of reproductive potential (girls who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months or have not undergone surgical sterilization [e.g., hysterectomy, bilateral oophorectomy, or salpingotomy]) must have a negative spot urine pregnancy test result (with a sensitivity of at least 50 mIU/mL) performed at entry, before initiating study medication.

• All subjects must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, donate sperm, or in vitro fertilization). If participating in sexual activity that could lead to pregnancy, the subject/partner must agree to use two reliable methods of contraception simultaneously (condoms with a spermicidal agent; or a diaphragm or cervical cap with spermicide) while on study drug and for 30 days after stopping the medication.

• Female subjects, who are not of reproductive potential, are eligible without requiring the use of contraception. Male subjects must use a condom with every sexual act that could lead to pregnancy.

NOTE: Acceptable documentation of sterilization is either written or oral documentation communicated by clinician or clinician's staff of one of the following: physician report/letter: operative report or other source documentation in the patient record (a laboratory report of azoospermia is required to document successful vasectomy); discharge summary; laboratory report of azoospermia; or FSH measurement elevated into the menopausal range as established by the reporting laboratory.

• Karnofsky performance score >= 80 within 30 days prior to study entry.

• Ability and willingness of subject to give written informed consent.

• Willingness to return for a follow-up visit on day 56.

• Subjects taking any precautionary concomitant medications (see section 5.2.2) must be on stable doses for >8 weeks prior to study entry and have no plans to change medications or doses for the duration of the study.

Exclusion Criteria:

• Receipt of anti-hepatitis C therapy within the 4 weeks prior to study entry or intent to initiate ant-hepatitis C therapy within 60 days after entry.

• Clinical evidence of cirrhosis or decompensated liver failure.

• Chronic or acute adrenal failure, history of active hepatitis B, HIV-1 infection, porphyrias, known moderate to severe cirrhosis, hemorrhagic disorders, concurrent anticoagulant therapy, any prior pituitary tumor, surgery, radiation treatment, or pituitary failure.

• Diabetes requiring treatment with oral hypoglycemics or insulin therapy.

• Pregnancy within 90 days prior to study entry.

• Breast-feeding.

• Dysfunctional uterine bleeding within the 12 months prior to study entry.

• Any current hormonal contraception or IUD use.

• Use of drugs that are inhibitors or inducers of metabolism by the CYP 3A4 within 7 days of study entry.

• Use of systemic corticosteroids or hormonal agents within 90 days prior to study entry.

• Use of any cytotoxic chemotherapy, immunomodulators or investigational therapy within 90 days prior to study entry.

• Any vaccination within 30 days prior to study entry.

• Allergy to mifepristone or its formulation.

• Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirement.

• Weight < 40 kg.

• Any other condition thought by the investigator that may interfere with the patient's ability to comply with the study protocol.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Connecticut	Farmington	Connecticut	United States	06030
2	Orlando Clinical Research Center	Orlando	Florida	United States	32809
3	Saint Louis University	Saint Louis	Missouri	United States	63104
4	University of Pennsylvania	Philadelphia	Pennsylvania	United States	19104

Sponsors and Collaborators

• VGX Pharmaceuticals, LLC

Investigators

• Principal Investigator: Bruce Bacon, M.D., St. Louis University
• Principal Investigator: Pablo Tebas, M.D., University of Pennsylvania
• Principal Investigator: George Wu, MD, University of Connecticut
• Principal Investigator: Thomas Marbury, MD, Orlando Clinical Research Center

Study Documents (Full-Text)

None provided.

More Information

Publications

• Kieft JS, Zhou K, Jubin R, Doudna JA. Mechanism of ribosome recruitment by hepatitis C IRES RNA. RNA. 2001 Feb;7(2):194-206.

• ClinicalTrials.gov Identifier: NCT00255177
• Other Study ID Numbers: VT003; Viral Genomix, Inc. (VGX); 450 Sentry Parkway; Blue Bell, PA 19422; C. Jo White, M.D.
• First Posted: Nov 17, 2005
• Last Update Posted: Nov 3, 2009
• Last Verified: Oct 1, 2009

• Keywords provided by , ,: Hepatitis C
• Additional relevant MeSH terms: Hepatitis A; Hepatitis C; Hepatitis; Mifepristone

Study Results

Participant Flow

Arm/Group Title	Placebo	VGX-410 150mg Daily	VGX-410 300mg Daily	VGX-410 300mg Twice Daily
Arm/Group Description
Period Title: Overall Study
STARTED	11	14	13	6
COMPLETED	9	13	12	4
NOT COMPLETED	2	1	1	2

Baseline Characteristics

Arm/Group Title	Placebo	VGX-410 150mg Daily	VGX-410 300mg Daily	VGX-410 300mg Twice Daily	Total
Arm/Group Description	Total of all reporting groups
Overall Participants	11	14	13	6	44
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	48.0 (6.9)	45.4 (6.9)	47.4 (9.2)	52.0 (3.7)	47.5 (6.7)
Sex: Female, Male (Count of Participants)
Female	5 45.5%	4 28.6%	3 23.1%	2 33.3%	14 31.8%
Male	6 54.5%	10 71.4%	10 76.9%	4 66.7%	30 68.2%
Region of Enrollment (participants) [Number]
United States	11 100%	14 100%	13 100%	6 100%	44 100%

Outcome Measures

1. Primary Outcome

Title	Mean Log Change in Viral Load From Baseline (Day 1) to Day 28
Description	Mean log change in HCV RNA viral load (significant reduction is considered >0.5 log 10) from baseline (Day 1) following once or twice daily dosing for 28 days at the 28 day timepoint
Time Frame	Baseline (Day 1) to Day 28

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Placebo	VGX-410 150mg Daily	VGX-410 300mg Daily	VGX-410 300mg Twice Daily
Arm/Group Description
Measure Participants	9	14	11	6
Log Mean (Standard Deviation) [copies/mL on log scale]	0.30 (0.45)	0.00 (0.30)	0.18 (0.32)	0.04 (0.39)

Adverse Events

Time Frame	AEs that occurred during treatment period (Days 1-28)
Arm/Group Title	Placebo		VGX-410 150mg Daily		VGX-410 300mg Daily		VGX-410 300mg Twice Daily
Arm/Group Description
All Cause Mortality
	Placebo		VGX-410 150mg Daily		VGX-410 300mg Daily		VGX-410 300mg Twice Daily
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)
Serious Adverse Events
	Placebo		VGX-410 150mg Daily		VGX-410 300mg Daily		VGX-410 300mg Twice Daily
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/11 (0%)		0/14 (0%)		1/13 (7.7%)		0/6 (0%)
Skin and subcutaneous tissue disorders
Generalized Rash	0/11 (0%)	0	0/11 (0%)	0	1/13 (7.7%)	1	0/6 (0%)	0
Other (Not Including Serious) Adverse Events
	Placebo		VGX-410 150mg Daily		VGX-410 300mg Daily		VGX-410 300mg Twice Daily
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	11/11 (100%)		14/14 (100%)		13/13 (100%)		6/6 (100%)
Ear and labyrinth disorders
Ear and Labyrinth Disorders	0/11 (0%)	0	1/14 (7.1%)	0	0/13 (0%)	0	0/6 (0%)	0
Eye disorders
Eye Disorders	0/11 (0%)	0	1/14 (7.1%)	0	3/13 (23.1%)	0	0/6 (0%)	0
Gastrointestinal disorders
Abdominal Distension	0/11 (0%)	0	0/14 (0%)	0	3/13 (23.1%)	0	0/6 (0%)	0
Abdominal Pain	0/11 (0%)	0	1/14 (7.1%)	0	2/13 (15.4%)	0	0/6 (0%)	0
Diarrhoea	1/11 (9.1%)		2/14 (14.3%)		0/13 (0%)	0	0/6 (0%)	0
Dry Mouth	1/11 (9.1%)		2/14 (14.3%)		3/13 (23.1%)		1/6 (16.7%)
Nausea	0/11 (0%)	0	4/14 (28.6%)	0	5/13 (38.5%)	0	2/6 (33.3%)	0
Vomiting	0/11 (0%)	0	3/14 (21.4%)	0	1/13 (7.7%)	0	1/6 (16.7%)	0
General disorders
Fatigue	3/11 (27.3%)		6/14 (42.9%)		3/13 (23.1%)		1/6 (16.7%)
Oedema Peripheral	0/11 (0%)	0	2/14 (14.3%)	0	2/13 (15.4%)	0	0/6 (0%)	0
Immune system disorders
Immune System Disorders	1/11 (9.1%)		0/14 (0%)	0	0/13 (0%)	0	0/6 (0%)	0
Infections and infestations
Infections and Infestations	2/11 (18.2%)		0/14 (0%)	0	1/13 (7.7%)	0	0/6 (0%)	0
Injury, poisoning and procedural complications
Injury, Poisoning and Procedural Complications	0/11 (0%)	0	2/14 (14.3%)	0	0/13 (0%)	0	0/6 (0%)	0
Investigations
Alanine Aminotransferase Increased	8/11 (72.7%)		8/14 (57.1%)		9/13 (69.2%)		4/6 (66.7%)
Aspartate Aminotransferase Increased	6/11 (54.5%)		8/14 (57.1%)		9/13 (69.2%)		5/6 (83.3%)
Blood Albumin Abnormal	1/11 (9.1%)		1/14 (7.1%)		2/13 (15.4%)		1/6 (16.7%)
Blood Bilirubin Increased	0/11 (0%)	0	1/14 (7.1%)	0	1/13 (7.7%)	0	2/6 (33.3%)	0
Blood Cholesterol Abnormal	1/11 (9.1%)		3/14 (21.4%)		1/13 (7.7%)		1/6 (16.7%)
Blood Glucose Abnormal	7/11 (63.6%)		8/14 (57.1%)		8/13 (61.5%)		4/6 (66.7%)
Blood Glucose Increased	1/11 (9.1%)		1/14 (7.1%)		0/13 (0%)	0	1/6 (16.7%)	0
Blood Potassium Increased	1/11 (9.1%)		1/14 (7.1%)		0/13 (0%)		1/6 (16.7%)
Blood Triglycerides Abnormal	1/11 (9.1%)		2/14 (14.3%)		0/13 (0%)		0/6 (0%)
Haemoglobin Decreased	2/11 (18.2%)		2/14 (14.3%)		2/13 (15.4%)		0/6 (0%)
Neutrophil Count Decreased	2/11 (18.2%)		2/14 (14.3%)		2/13 (15.4%)		1/6 (16.7%)
Platelet Count Decreased	1/11 (9.1%)		1/14 (7.1%)		3/13 (23.1%)		1/6 (16.7%)
White Blood Cell Count Decreased	2/11 (18.2%)		2/14 (14.3%)		0/13 (0%)		2/6 (33.3%)
Metabolism and nutrition disorders
Metabolism and Nutrition Disorders	1/11 (9.1%)		0/14 (0%)		1/13 (7.7%)		0/6 (0%)
Musculoskeletal and connective tissue disorders
Musculoskeletal and Connective Tissue Disorders	2/11 (18.2%)		4/14 (28.6%)		3/13 (23.1%)		0/6 (0%)
Back Pain	1/11 (9.1%)		1/14 (7.1%)		1/13 (7.7%)		0/6 (0%)
Nervous system disorders
Dizziness	1/11 (9.1%)		3/14 (21.4%)		3/13 (23.1%)		0/6 (0%)
Dizziness Postural	1/11 (9.1%)		1/14 (7.1%)		0/13 (0%)		1/6 (16.7%)
Headache	3/11 (27.3%)		5/14 (35.7%)		2/13 (15.4%)		1/6 (16.7%)
Psychiatric disorders
Anxiety	1/11 (9.1%)		1/14 (7.1%)		1/13 (7.7%)		1/6 (16.7%)
Reproductive system and breast disorders
Reproductive System and Breast Disorders	0/11 (0%)		3/14 (21.4%)		2/13 (15.4%)		0/6 (0%)
Respiratory, thoracic and mediastinal disorders
Cough	0/11 (0%)		1/14 (7.1%)		1/13 (7.7%)		1/6 (16.7%)
Sinus Congestion	1/11 (9.1%)		1/14 (7.1%)		2/13 (15.4%)		0/6 (0%)
Skin and subcutaneous tissue disorders
Pruritis	0/11 (0%)		2/14 (14.3%)		1/13 (7.7%)		1/6 (16.7%)
Surgical and medical procedures
Surgical and Medical Procedures	0/11 (0%)		0/14 (0%)		0/13 (0%)		1/6 (16.7%)
Vascular disorders
Hot Flush	1/11 (9.1%)		3/14 (21.4%)		1/13 (7.7%)		0/6 (0%)
Orthostatic Hypotension	1/11 (9.1%)		1/14 (7.1%)		1/13 (7.7%)		0/6 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.